Catalytic Deoxyribozyme-Modified Nanoparticles for RNAi-Independent Gene Regulation

• Published in: ACS nano Vol. 6; no. 10; pp. 9150 - 9157
• Main Authors: Yehl, Kevin, Joshi, Jayashree P, Greene, Brandon L, Dyer, R. Brian, Nahta, Rita, Salaita, Khalid
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 23.10.2012
• Subjects: Biomedical materials; Catalysis; Catalysts; Gene expression; Gene Expression Regulation - drug effects; Gene Expression Regulation - genetics; Gold; Humans; In vivo testing; In vivo tests; Nanocapsules - chemistry; Nanocapsules - ultrastructure; RNA - administration & dosage; RNA - genetics; RNA Interference; Surface chemistry; Surgical implants; Transfection - methods; DNAzyme; Herceptin; trastuzumab; synthetic biology; deoxyribozyme; gold nanoparticle; gene regulation; GDF15; breast cancer
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/nn3034265

DNAzymes are catalytic oligonucleotides with important applications in gene regulation, DNA computing, responsive soft materials, and ultrasensitive metal-ion sensing. The most significant challenge for using DNAzymes in vivo pertains to nontoxic delivery and maintaining function inside cells. We synthesized multivalent deoxyribozyme “10-23” gold nanoparticle (DzNP) conjugates, varying DNA density, linker length, enzyme orientation, and linker composition in order to study the role of the steric environment and gold surface chemistry on catalysis. DNAzyme catalytic efficiency was modulated by steric packing and proximity of the active loop to the gold surface. Importantly, the 10-23 DNAzyme was asymmetrically sensitive to the gold surface and when anchored through the 5′ terminus was inhibited 32-fold. This property was used to generate DNAzymes whose catalytic activity is triggered by thiol displacement reactions or by photoexcitation at λ = 532 nm. Importantly, cell studies revealed that DzNPs are less susceptible to nuclease degradation, readily enter mammalian cells, and catalytically down-regulate GDF15 gene expression levels in breast cancer cells, thus addressing some of the key limitations in the adoption of DNAzymes for in vivo work.